Cargando…

Transcriptome-Based Co-Expression of BRD4 and PD-1/PD-L1 Predicts Poor Overall Survival in Patients With Acute Myeloid Leukemia

Positive response to PD-1/PD-L1 blockades was observed in the treatment of solid tumors. However, the clinical response to PD-1/PD-L1 blockade varied in patients with acute myeloid leukemia (AML). It is thought that there are factors other than PD-1 and PD-L1 that may affect the effect of immunother...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Cunte, Xu, Ling, Gao, Rili, Wang, Shunqing, Zhang, Yuping, Wang, Caixia, Zeng, Chengwu, Li, Yangqiu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917577/ https://www.ncbi.nlm.nih.gov/pubmed/33658927 http://dx.doi.org/10.3389/fphar.2020.582955

Ejemplares similares

High expression of LOC541471, GDAP1, SOD1, and STK25 is associated with poor overall survival of patients with acute myeloid leukemia
por: Yu, Xibao, et al.
Publicado: (2023)

Expression patterns of immune checkpoints in acute myeloid leukemia
por: Chen, Cunte, et al.
Publicado: (2020)

BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
por: Zhong, Mengjun, et al.
Publicado: (2022)

Correction to: BET bromodomain inhibition rescues PD-1-mediated T-cell exhaustion in acute myeloid leukemia
por: Zhong, Mengjun, et al.
Publicado: (2022)

TNFAIP3 mutation is an independent poor overall survival factor for patients with T‐cell acute lymphoblastic leukemia
por: Chen, Cunte, et al.
Publicado: (2022)

Increased PD-1(+)Foxp3(+) γδ T cells associate with poor overall survival for patients with acute myeloid leukemia
por: Zheng, Jiamian, et al.
Publicado: (2022)

Higher TOX Genes Expression Is Associated With Poor Overall Survival for Patients With Acute Myeloid Leukemia
por: Liang, Chaofeng, et al.
Publicado: (2021)

High expression of TMEM244 is associated with poor overall survival of patients with T-cell lymphoma
por: Chen, Cunte, et al.
Publicado: (2022)

lncRNA-CCDC26, as a novel biomarker, predicts prognosis in acute myeloid leukemia
por: Chen, Cunte, et al.
Publicado: (2019)

Low Expression of CD5 and CD6 Is Associated with Poor Overall Survival for Patients with T-Cell Malignancies
por: Sui, Songnan, et al.
Publicado: (2022)

Current insight into the regulation of PD-L1 in cancer
por: Liu, Zhuandi, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases
por: Zhang, Ke, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

BCL11B Mutations Are Associated with Higher CD8+ T-Cell Percentage and Favorable Clinical Outcomes in Patients with T-Cell Acute Lymphoblastic Leukemia
por: Chen, Cunte, et al.
Publicado: (2023)

Optimal combination of immune checkpoint and senescence molecule predicts adverse outcomes in patients with acute myeloid leukemia
por: Wang, Peipei, et al.
Publicado: (2023)

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy
por: Liu, Jinhua, et al.
Publicado: (2021)

NRF2 activation induced by PML‐RARα promotes microRNA 125b‐1 expression and confers resistance to chemotherapy in acute promyelocytic leukemia
por: Yu, Xibao, et al.
Publicado: (2021)

Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?
por: Jimbu, Laura, et al.
Publicado: (2021)

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism
por: Dong, Hao, et al.
Publicado: (2022)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
por: Qi, Yihang, et al.
Publicado: (2021)

PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake
por: Zhang, Jian-ye, et al.
Publicado: (2020)

Emerging Role of PD-1/PD-L1 Inhibitors in Chronic Liver Diseases
por: Singh, Vishakha, et al.
Publicado: (2021)

Editorial: Targeting the PD-1/PD-L1 Cancer Immune Evasion Axis: Challenges and Emerging Strategies
por: Wang, Yiting, et al.
Publicado: (2020)

Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia
por: Yang, Xingcheng, et al.
Publicado: (2022)

β-Glucan Combined With PD-1/PD-L1 Checkpoint Blockade for Immunotherapy in Patients With Advanced Cancer
por: Wang, Mengjie, et al.
Publicado: (2022)

Value assessment of PD-1/PD-L1 inhibitors in the treatment of oesophageal and gastrointestinal cancers
por: Ou, Shun-Long, et al.
Publicado: (2023)

Prognostic nomogram for adult patients with acute myeloid leukemia: A SEER database analysis
por: Chen, Cunte, et al.
Publicado: (2019)

Editorial: Toxicity mechanism and clinical features of PD-1/PD-l1 inhibitors in treatment of cancer, volume II
por: Lei, Chuqi, et al.
Publicado: (2023)

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
por: Wang, Peng-Fei, et al.
Publicado: (2017)

Anti-PD-1/PD-L1 for nasopharyngeal carcinoma: a comprehensive analysis of registered trials on ClinicalTrials.gov
por: Dai, Zelei, et al.
Publicado: (2023)

Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer
por: Wang, Man, et al.
Publicado: (2023)

Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
por: Feng, Yuqian, et al.
Publicado: (2021)

The importance of genomic predictors for clinical outcome of hematological malignancies
por: Chen, Cunte, et al.
Publicado: (2021)

Inhibition of BCL11B induces downregulation of PTK7 and results in growth retardation and apoptosis in T-cell acute lymphoblastic leukemia
por: Li, Kehan, et al.
Publicado: (2021)

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
por: Alsaab, Hashem O., et al.
Publicado: (2017)

Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
por: Chocarro de Erauso, Luisa, et al.
Publicado: (2020)

Safety and Efficacy of Anti-PD-1/PD-L1 Inhibitors Compared With Docetaxel for NSCLC: A Systematic Review and Meta-Analysis
por: Ma, Long, et al.
Publicado: (2021)

Efficacy and safety of PD-1 and PD-L1 inhibitors combined with chemotherapy in randomized clinical trials among triple-negative breast cancer
por: Qi, Yihang, et al.
Publicado: (2022)

Management of Adverse Events in Cancer Patients Treated With PD-1/PD-L1 Blockade: Focus on Asian Populations
por: Yang, Jiqiao, et al.
Publicado: (2019)

Editorial: Toxicity Mechanism and Clinical Features of PD-1/PD-L1 Inhibitors in Treatment of Cancer, Volume I
por: Kong, Xiangyi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bh0k0151elbdjthlsv0nprf45s